Morgan Stanley on Compass Pathways (CMPS): 'we view today’s update as incrementally encouraging'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Morgan Stanley on Compass Pathways (CMPS): 'we view today’s update as incrementally encouraging'

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher

April 24, 2026 10:37 AM EDT

Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standards FDA grants Compass NDA rolling submission and review request, based on Phase 3 data CNPV awarded for COMP360, Compass proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD) CNPV further accelerates momentum and Compass is confident and ready to deliver for patients

LONDON & NEW YORK--(BUSINESS... More